Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Skull base versus non-skull base meningioma surgery in the elderly

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Rare cause of spontaneous haemothorax: mediastinal and distant lymph node metastases from uveal melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Transcriptome analysis in patients with temporal lobe epilepsy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Publisher Correction: Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Pilocytic astrocytoma (PA) is one of the most common brain cancers among children and activation of the Mitogen-Activated Protein Kinase (MAPK) pathway is considered the hallmark. In the majority of cases, oncogenic BRAF fusions or BRAF V600E mutations are observed, while RAF1 or NF1 alterations are more rarely found. However, in some cases, no apparent cancer driver events can be identified. Here, we describe a novel fusion between the transcription factor nuclear factor 1A (NFIA) and Raf-1 proto-oncogene (RAF1) in a 5-year old boy with PA. The novel fusion was identified as part of a comprehensive genomic tumor profiling. We show that the NFIA:RAF1 fusion results in constitutive Raf1 kinase activity, leading to activation of downstream MEK1/2 cascade and increased proliferation of cancer cells. The NFIA:RAF1 fusion displayed distinct subcellular localization towards the plasma membrane indicative of Raf-1 activation, in contrast to both wild type NFIA and Raf-1, which were localized in the nucleus and cytoplasm, respectively. In conclusion, our data support the existence of rare oncogenic RAF1 fusions with constitutive Raf-1 activity. This highlights the need for broad genetic testing in order to refine diagnostics of PA and to unravel potential treatment options, e.g. with MEK inhibitors.

OriginalsprogEngelsk
TidsskriftCancer genetics
Vol/bind209
Udgave nummer10
Sider (fra-til)440-444
Antal sider5
ISSN2210-7762
DOI
StatusUdgivet - okt. 2016

ID: 49285066